VistaGen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Mkt Cap: US$62.1m

VistaGen Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Shawn Singh (59 yo)

23.08yrs

Tenure

US$1,182,460

Compensation

Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....


CEO Compensation Analysis

How has Shawn Singh's remuneration changed compared to VistaGen Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$60m

Mar 31 2022US$1mUS$563k

-US$49m

Dec 31 2021n/an/a

-US$62m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021US$1mUS$511k

-US$42m

Dec 31 2020n/an/a

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020US$934kUS$498k

-US$22m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019US$951kUS$466k

-US$26m

Dec 31 2018n/an/a

-US$24m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018US$1mUS$425k

-US$16m

Dec 31 2017n/an/a

-US$14m

Sep 30 2017n/an/a

-US$13m

Jun 30 2017n/an/a

-US$12m

Mar 31 2017US$1mUS$385k

-US$12m

Dec 31 2016n/an/a

-US$18m

Sep 30 2016n/an/a

-US$19m

Jun 30 2016n/an/a

-US$24m

Mar 31 2016US$2mUS$348k

-US$51m

Compensation vs Market: Shawn's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD724.43K).

Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director13.5yrsUS$1.18m0.38%
$ 235.6k
Jerrold Dotson
Chief Financial Officer11.42yrsUS$712.11k0.051%
$ 31.5k
Reid Adler
Chief Corporate Development & Legal Officer0.75yrno data0.16%
$ 100.4k
Joshua Prince
Senior Vice President of Business Operations0.25yrno datano data
Mark Flather
Vice President of Investor Relationsno datano datano data
Trisha Fitzmaurice
Vice President of Human Resourcesno datano datano data
Allen Cato
Senior Vice President of Development Operationsno datano datano data
Mark Ginski
Senior VP and Head of Chemistry2yrsno datano data
Jaakko Lappalainen
Senior Vice President of Medical Research & Pharmacovigilanceno datano datano data
Jessica Haskell
VP, Associate General Counsel & Corporate Secretary0.50yrno datano data

1.4yrs

Average Tenure

63.5yo

Average Age

Experienced Management: VTGN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director23.08yrsUS$1.18m0.38%
$ 235.6k
Jon Saxe
Independent Chairman23.08yrsUS$160.64k0.027%
$ 16.7k
Jerry Gin
Independent Director6.92yrsUS$160.95k0.19%
$ 120.0k
Gordon Keller
Chairman of Scientific Advisory Board0.17yrno datano data
Thomas Laughren
Member of Clinical & Regulatory Advisory Board6.92yrsno datano data
Maurizio Fava
Member of Clinical & Regulatory Advisory Board7.33yrsno datano data
Michael Liebowitz
Member of CNS Clinical and Regulatory Advisory Board4.33yrsno datano data
Mark Steven Wallace
Member of Clinical & Regulatory Advisory Board5.58yrsno datano data
Gerard Sanacora
Member of Clinical & Regulatory Advisory Board8yrsno datano data
Mary Rotunno
Independent Director1.58yrsUS$305.50k0%
$ 0
Ann Cunningham
Director1.08yrsUS$1.25m0%
$ 0
Sanjay Mathew
Member of Clinical & Regulatory Advisory Board6.92yrsno datano data

6.9yrs

Average Tenure

62yo

Average Age

Experienced Board: VTGN's board of directors are considered experienced (6.9 years average tenure).